Skip to main content
Andrew Blauvelt, MD, Dermatology, Annapolis, MD

Andrew Blauvelt MD MBA

Dermatology•Annapolis, MD

Consultant, Blauvelt Consulting, LLC

Join to view full profile

  • 533 Saltworks CourtAnnapolis, MD 21401

  • Phone+1 503-888-5225

Dr. Blauvelt is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Blauvelt's full profileAlready have an account?

Summary

  • Dr. Blauvelt is Adjunct Professor in the Department of Dermatology at the University of Maryland School of Medicine and is Owner of Blauvelt Consulting, LLC. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief) as well as being Owner and President of Oregon Medical Research Center (OMRC) from 2013-2022. Dr. Blauvelt has published over 475 papers and spoken across the country and world on scientific and clinical aspects of inflammatory skin diseases. Within psoriasis immunology research, his laboratory published key papers on the role of IL-23/Th17 biology in this disease. In recent years, he was the international lead/senior investigator on numerous important clinical trials, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, BE ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, POETYK PSO-1, ONWARD 1 and 2, CHRONOS, ECZTEND, JADE REGIMEN, HEADS UP, ADhere, and KNOCKOUT. He is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, and the International Eczema Council. In 2023, he became Chair of the Medical Board for the National Psoriasis Foundation, an organization he has worked closely with for over 25 years in a variety of capacities.

Education & Training

  • Portland State University
    Portland State UniversityM.B.A., Healthcare Management, 2010 - 2013
  • University of Miami/Jackson Health System
    University of Miami/Jackson Health SystemResidency, Dermatology, 1989 - 1992
  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalInternship, Internal Medicine, 1988 - 1989
  • Michigan State University College of Human Medicine
    Michigan State University College of Human MedicineClass of 1988
  • Purdue University System
    Purdue University SystemB.S., Electrical Engineering, 1980 - 1984

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1991 - 2028
  • OR State Medical License
    OR State Medical License 2004 - 2027
  • MI State Medical License
    MI State Medical License 1988 - 1989
  • Dermatology
    American Board of Dermatology Dermatology
  • Clinical & Laboratory Dermatological Immunology
    American Board of Dermatology Clinical & Laboratory Dermatological Immunology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis  
    Andrew Blauvelt, Steven Kempers, Stephen Tyring, Glynis Ablon, The New England Journal of Medicine
  • Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis  
    Andrew Blauvelt, Craig L Leonardi, Jashin J Wu, JAMA Dermatology
  • Certolizumab Pegol for the Treatment of Patients with Moderate‐to‐Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials  
    Andrew Blauvelt, MD, Journal of The European Academy of Dermatology and Venereology

Books/Book Chapters

  • Moderate to Severe Psoriasis 
    Chapter: Ustekinumab. 
    Page 217 - 230Blauvelt AEditors: Levin E, Leon A, Wu JJ, Gottlieb AB, Koo JYM.CRC Press, Boca Raton, FLEdition 4th,2014
  • Moderate-to-Severe Psoriasis 
    Chapter: Ustekinumab and ABT-874. 
    Page 347 - 364Blauvelt AEditors: Koo JYM, Lee CS, Lebwohl MG, Weinstein GD, Gottlieb A.Informa Healthcare, New York, NYEdition 3rd,2009
  • Fitzpatrick's Dermatology in General Medicine 
    Chapter: Skin Disease in Acute and Chronic Immunosuppression. 
    Page 267 - 278Kauls L, Blauvelt AEditors: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ.The McGraw-Hill Companies, Inc., New York, NYEdition 7th,2008

Abstracts/Posters

  • Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis (poster).
    Blauvelt A, 44th Annual European Society for Dermatological Research Meeting, Copenhagen, Denmark, 9/1/2014
  • Candidiasis in secukinumab-treated subjects is non-serious and transient: a pooled analysis of data from 10 phase 2 and 3 clinical trials in psoriasis (poster).
    Blauvelt A, Federation of Clinical Immunology Societies Annual Meeting, Chicago, IL, 6/1/2014
  • Secukinumab efficacy and safety: results from the first study of secukinumab in prefilled syringes in subjects with chronic plaque-type psoriasis response at 12 weeks ...
    Blauvelt A, Dermatology Nurses’ Association Annual Meeting, Orlando, FL, 5/1/2014

Lectures

  • Late-breaking Research: Clinical Trials 
    American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
  • Crossfire symposium: the advent of biosimilars (invited speaker). 
    Amsterdam, Netherlands - 10/1/2014
  • JAK inhibitors as treatment in psoriasis: understanding efficacy (invited speaker). 
    Copenhagen, Denmark - 9/1/2014

Other

Authored Content

  • Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque PsoriasisApril 2020

Press Mentions

  • Super Response to Biologics for Skin Diseases Often Predicts Sustained Benefit
    Super Response to Biologics for Skin Diseases Often Predicts Sustained BenefitOctober 3rd, 2025
  • Mounting Evidence for Psoriasis Cure
    Mounting Evidence for Psoriasis CureApril 25th, 2025
  • Two Oral TYK2 Inhibitors Enter Phase 3 Trials for Plaque Psoriasis on Basis of Phase 2 Promise
    Two Oral TYK2 Inhibitors Enter Phase 3 Trials for Plaque Psoriasis on Basis of Phase 2 PromiseApril 3rd, 2025

Grant Support

  • Role Of IL-23 In Psoriasis PathogenesisNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007–2008
  • The Role Of Kaposi'S Sarcoma-Associated Herpesvirus In TDivision Of Clinical Sciences - Nci2002–2003
  • Langerhans Cells In Immunopathogenesis Of HIV DiseaseDivision Of Clinical Sciences - Nci2001–2003
  • The Role Of Langerhans Cells In The Immunopathogenesis ODivision Of Clinical Sciences - Nci2002
  • Novel Translational Studies For PsoriasisDivision Of Clinical Sciences - Nci2001–2002

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Andrew Blauvelt, Dr. Andrew Blauvelt, MD, Dr. A Blauvelt